AASK-CO

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 AASK队列研究是一项前瞻性、观察性研究，是AASK临床试验的延伸。霍华德大学将在AASK队列研究中招募29人。 此外，那些到达ESRD的AASK参与者将被邀请参加一次DNA采集访视。 每年收集两次暴露，包括环境、遗传、生理和社会经济因素。 主要结局将定义为血清肌酐加倍、进展为ESRD或死亡。将为未患有ESRD的受试者提供适当的降压治疗。 以这种方式，队列将直接控制肾脏疾病进展的两个主要“已知”决定因素（治疗高血压和使用肾脏保护性降压药物），因此，将在推荐的高血压治疗环境中解决其研究目标。 4-6每年将为每位参与者进行BP控制联系。 队列研究的随访持续时间为5年。AASK队列研究将提供数据，增强我们对决定肾脏疾病进展的过程的理解。 此外，这项研究的数据可能最终导致延迟或预防ESRD发作的新预防策略。 主要目的是前瞻性确定接受推荐降压治疗的高血压相关肾病非裔美国人的肾功能长期病程和肾脏疾病进展的风险因素。 次要目的是确定心血管疾病的发生率，并评估其在高血压相关肾脏疾病背景下的危险因素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK Clinical trial. Howard University will enroll 29 in the AASK Cohort Study. Additionally, those AASK participants who reached ESRD will be invited to attend one visit for collection of DNA. Exposures to be collected twice/year including environmental, genetic, physiologic and socioeconomic factors. The primary outcome will be defined by the doubling of serum creatinine, progression to ESRD or death. Appropriate antihypertensive treatment will be provided to participants who do not have ESRD. In this fashion, the Cohort will directly control two of the major "known" determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medications) and will, therefore, address its research objectives in the setting of recommended hypertensive care. 4-6 contacts for BP control will take place per year for each participant. The duration of followup in the Cohort Study will be 5 years. The AASK Cohort Study will provide data that enhances our understanding of the processes that determine progression of renal disease. Furthermore, data from this study might ultimately lead to new prevention strategies that delay or prevent the onset of ESRD. The primary objective is to prospectively determine the long-term course of kidney function and risk factors for kidney disease progression in African Americans with hypertension-related kidney disease who receive recommended antihypertension therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors in the setting of hypertension-related kidney disease.